IL-2Rβ Inhibitors
The class of IL-2Rβ inhibitors encompasses a diverse array of chemicals that intricately modulate immune signaling pathways to achieve selective inhibition of IL-2Rβ. Cyclosporin A and tacrolimus, both calcineurin inhibitors, indirectly inhibit IL-2Rβ by disrupting the calcineurin-NFAT pathway, crucial for IL-2Rβ-mediated T cell activation. Monoclonal antibodies, such as basiliximab and daclizumab, directly inhibit IL-2Rβ by interfering with the IL-2 receptor complex formation, offering a precise mechanism to disrupt IL-2Rβ-mediated immune responses.
Everolimus, sirolimus, and rapamycin, mTOR inhibitors, indirectly inhibit IL-2Rβ by disrupting downstream signaling events essential for T cell activation. Belatacept, a fusion protein, indirectly inhibits IL-2Rβ by blocking CD28-mediated co-stimulation, disrupting downstream signaling events crucial for IL-2Rβ-dependent pathways. Sotrastaurin, a PKC inhibitor, and Ruxolitinib and tofacitinib, JAK inhibitors, indirectly inhibit IL-2Rβ by targeting key kinases involved in T cell receptor signaling. Dasatinib, a SFK inhibitor, indirectly inhibits IL-2Rβ by modulating Src family kinases, providing a targeted approach to regulate IL-2Rβ-dependent pathways involved in immune responses. The shared theme among these inhibitors lies in their ability to navigate the intricate immune signaling networks and selectively modulate IL-2Rβ-dependent pathways, showcasing the diverse strategies employed for achieving immunomodulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits IL-2Rβ by forming a complex with cyclophilin and calcineurin, leading to the inhibition of the nuclear factor of activated T cells (NFAT) signaling pathway. This complex prevents the dephosphorylation and nuclear translocation of NFAT, which is crucial for IL-2Rβ-mediated T cell activation and IL-2 expression. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Tacrolimus inhibits IL-2Rβ by forming a complex with FK506-binding protein 12 (FKBP12) and calcineurin, similar to cyclosporin A. This complex inhibits calcineurin activity, preventing the dephosphorylation and activation of NFAT. By targeting the calcineurin-NFAT pathway, tacrolimus indirectly inhibits IL-2Rβ signaling, disrupting the T cell activation cascade and IL-2 expression. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits IL-2Rβ indirectly by targeting the mammalian target of rapamycin (mTOR) pathway. By forming a complex with FKBP12, everolimus inhibits mTOR, disrupting downstream signaling events essential for IL-2Rβ-mediated T cell activation. The inhibition of mTOR by everolimus illustrates its indirect inhibitory effect on IL-2Rβ, providing a molecular basis for its immunosuppressive actions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus (Rapamycin) inhibits IL-2Rβ indirectly by forming a complex with FKBP12 and inhibiting mTOR. The disruption of mTOR signaling by sirolimus interferes with downstream events crucial for IL-2Rβ-mediated T cell activation, highlighting the indirect inhibitory mechanism employed by sirolimus in modulating IL-2Rβ-dependent immune responses. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin inhibits IL-2Rβ indirectly by targeting protein kinase C (PKC), a key regulator of T cell activation. By inhibiting PKC, sotrastaurin disrupts downstream signaling events essential for IL-2Rβ-mediated T cell activation and IL-2 expression. The indirect inhibition of IL-2Rβ by sotrastaurin through PKC modulation provides a mechanistic insight into its immunosuppressive actions. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib inhibits IL-2Rβ indirectly by targeting Janus kinase (JAK) signaling, specifically JAK1 and JAK2. By inhibiting JAKs, ruxolitinib disrupts downstream signaling events essential for IL-2Rβ-mediated T cell activation and immune responses. The indirect inhibition of IL-2Rβ by ruxolitinib through JAK modulation provides a targeted approach to regulate IL-2Rβ-dependent pathways involved in inflammatory processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits IL-2Rβ indirectly by targeting Src family kinases (SFKs), which play a role in T cell receptor signaling. By inhibiting SFKs, dasatinib disrupts downstream signaling events crucial for IL-2Rβ-mediated T cell activation and immune responses. The indirect inhibition of IL-2Rβ by dasatinib through SFK modulation provides a mechanistic insight into its immunomodulatory actions. | ||||||